BioCentury | Apr 1, 2013
Clinical News
Viscogel: Phase I/II data
...single-blind, Swedish Phase I/II trial in about 130 healthy volunteers showed that single ascending-doses of ViscoGel...
...ViVac, a project aimed at developing ViscoGel as an adjuvant in prophylactic and therapeutic vaccination. Viscogel...
...part of ViVac. Sanofi (Euronext:SAN; NYSE:SNY, Paris, France) markets ActHIB. Viscogel AB , Solna, Sweden Product: Viscogel...
...ViVac, a project aimed at developing ViscoGel as an adjuvant in prophylactic and therapeutic vaccination. Viscogel...
...part of ViVac. Sanofi (Euronext:SAN; NYSE:SNY, Paris, France) markets ActHIB. Viscogel AB , Solna, Sweden Product: Viscogel...